Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033

Although the disorder is rare, it causes life-long impairment and severe symptoms requiring treatments such as antiepileptics and supportive therapies. Only one drug is USFDA approved for the treatment of RTT: Daybue (trofinetide), which is marketed by Acadia Pharmaceuticals. The drug could help in improving communication, interaction and multiple other features of RTT. However, it cannot cure the condition and opportunities remain for drug development for managing the condition. Although the...

Although the disorder is rare, it causes life-long impairment and severe symptoms requiring treatments such as antiepileptics and supportive therapies. Only one drug is USFDA approved for the treatment of RTT: Daybue (trofinetide), which is marketed by Acadia Pharmaceuticals. The drug could help in improving communication, interaction and multiple other features of RTT. However, it cannot cure the condition and opportunities remain for drug development for managing the condition.

The broad opportunity areas in RTT include,

Closing statement: Successfully targeting these opportunities would help drug marketers to capture substantial patient share in RTT and achieve commercial success.

Commercial Potential:

Thelansis's report on Rett Syndrome provides in-depth insights on the disease and patient segments, along with the areas of unmet need and drug development pipeline. The report answers key questions such as,

KOL perspectives:

"I believe that all diagnosed patients for Rett Syndrome receive one or the other drug therapy. However, current treatments are focused on improving symptoms of Rett Syndrome. We need a disease-modifying therapy to resolve the condition." ~A U.S.-based neurologist

 "Gene therapy would be a promising treatment approach to solve the problem associated with proteins." ~A Europe-based neurologist

About Thelansis:

Thelansis specializes in pharmaceutical and biopharmaceutical business research and consulting Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indications. Over the period, we have built a strong repository of 6,000+ Bio-pharma reports which essentially cover Epidemiology studies and Market forecasting, opportunity assessment based on the KOL Interviews and conference coverage. Competitive intelligence and conference coverage throughout the phases of asset development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

Offerings in the orphan indications:

syndicated reports/offerings for the major markets, epidemiology, customized market research including KOL interviews, PMR surveys, pipeline research, conference coverage, market forecast models, and consulting.

The developers and marketers for drugs in orphan indications can engage Thelansis for customized market research and can gain on possible solutions for ensuring considerable market penetration for their respective therapies.

Contact us today on ….

Website: Thelansis.com

For more information, please contact: 
Chinmaya Kumar Senapati
Email- clientsupport@thelansis.com
Contact No.-+91-6397349664

Logo: https://mma.prnewswire.com/media/2336260/THELANSIS_LOGO.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/rett-syndrome---market-outlook-epidemiology-competitive-landscape-and-market-forecast-report-2023-to-2033-302111846.html